期刊
CANCER AND METASTASIS REVIEWS
卷 33, 期 2-3, 页码 567-579出版社
SPRINGER
DOI: 10.1007/s10555-013-9472-2
关键词
Androgen receptor; Prostate cancer; CYP17; Abiraterone; Enzalutamide
类别
资金
- Cancer Research UK
- Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre
After decades of limited success in the treatment of castration-resistant prostate cancer (CRPC), five novel therapeutics were granted Food and Drug Administration regulatory approval in the last 4 years based on several randomized phase III studies that have reported a survival benefit. Among them, two drugs targeting the androgen receptor pathway, namely abiraterone acetate and enzalutamide, have demonstrated that targeting androgen signalling following progression to classical androgen blockade continues to be an effective strategy despite the emergence of resistance mechanisms to sequential treatments. In addition to these two approved drugs, several other promising agents that block steroidogenesis interact with the androgen receptor or modulate post-receptor signal transduction that are undergoing clinical evaluation. This issue reviews the current data and the state of development of novel androgen receptor-targeting drugs and further discusses how this revolution in therapeutic armamentarium for the treatment of CRPC has raised challenges for clinicians about the optimal usage of these compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据